Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$70.10 USD

70.10
1,222,449

-0.19 (-0.27%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $70.22 +0.12 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Arpita Dutt headshot

Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More

Key highlights in the biotech sector include mixed data from Cara (CARA) and regulatory updates from companies like BioMarin.

    BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase

    BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).

      Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?

      Shares of Catalyst Pharmaceuticals, Inc. (CPRX) have soared 161% this year so far, massively outperforming the Zacks classified Medical Drugs industry's gain of 10.2%.

        BioMarin (BMRN) in Focus: Stock Moves 7% Higher

        BioMarin (BMRN) was a big mover last session, as the company saw its shares rise 7% on the day.

          BioMarin (BMRN) Down 8% Since Earnings Report: Can It Rebound?

          BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            BioMarin's (BMRN) Brineura Approved by European Commission

            BioMarin Pharmaceutical Inc. (BMRN) announced that the European Commission has approved Brineura (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2).

              Ultragenyx Receives Priority Review for rhGUS from FDA

              The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.

                BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up

                BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.

                  Tirthankar Chakraborty headshot

                  New Strong Buy Stocks for May 5th

                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

                    Why Earnings Season Could Be Great for BioMarin (BMRN)

                    BioMarin (BMRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                      Arpita Dutt headshot

                      Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update

                      Earnings were in focus this week with companies like Amgen (AMGN), Celgene, Vertex, AbbVie, Alexion and Gilead all reporting results over the last few days.

                        What Lies Ahead for Stericycle (SRCL) this Earnings Season?

                        Waste management firm Stericycle, Inc. (SRCL) is scheduled to report first-quarter 2017 results after the closing bell on May 4.

                          Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?

                          Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report first-quarter results on May 4 before market open.

                            BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?

                            We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.

                              Arpita Dutt headshot

                              Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug

                              Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.

                                Arpita Dutt headshot

                                Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed

                                Incyte's (INCY) shares were hit by the FDA's complete response letter (CRL) for the company's rheumatoid arthritis drug.

                                  Arpita Dutt headshot

                                  5 Drug Stocks That Could Be Big Winners this Earnings Season

                                  Here is a look at five companies including Pfizer (PFE) that sport a favorable Zacks Rank and have a positive earnings ESP.

                                    Arpita Dutt headshot

                                    4 FDA Decisions to Watch Out for in Apr 2017

                                    Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month.

                                      Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report?

                                      BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse

                                        We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22.

                                          Repros (RPRX) Q4 Earnings: What's in Store for the Stock?

                                          Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.

                                            Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?

                                            Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report fourth-quarter 2016 results this month.

                                              Inovio (INO): What's in the Cards this Earnings Season?

                                              Inovio Pharmaceuticals, Inc. (INO) is expected to report fourth-quarter 2016 results this month. The company incurred wider-than-expected loss in the last quarter.

                                                BioDelivery (BDSI): What's in Store this Earnings Season?

                                                BioDelivery Sciences International, Inc. (BDSI) is expected to report fourth-quarter 2016 results on Mar 17, before the opening bell. Last quarter, the company???s loss was wider than expected.

                                                  What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?

                                                  Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.